Company / Operating Cash Flow
AVADEL PHARMACEUTICALS PLC Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$46.9M
FY2024
5-year range
-$128.5M / -$46.9M
FY2020-FY2024
Trend
+63.5%
vs FY2023
Sector context
#95 of 216
Health Care
What the data says
At -$47M, AVADEL PHARMACEUTICALS PLC's operating cash flow ranks #95 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$129M in FY2023 to $84M in FY2015.
Based on SEC 10-K filings.
-$47M in FY2024.
Improved from -$70M to -$47M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#95 of 216 in Health CareTop 44% of 216This company -$46.9M Sector average $658.7M
▼
-107.1% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow increased 63.5% year-over-year.
- Ranks #95 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2015.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$46.9M | +63.5% |
| FY2023 | -$128.5M | -82.8% |
| FY2022 | -$70.3M | +9.1% |
| FY2021 | -$77.3M | -58.6% |
| FY2020 | -$48.7M | -27.2% |
| FY2019 | -$38.3M | +53.7% |
| FY2018 | -$82.7M | -596.4% |
| FY2017 | $16.7M | -11.8% |
| FY2016 | $18.9M | -77.6% |
| FY2015 | $84.3M | +893.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026